ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

December 12, 2003

NCI Funded Over 4,500 Grants Last Year, Half Its $3B Budget.

January 19, 2001

Decline In Breast Cancer May Be Related to Drop In HT

March 25, 2011

DeVita Accepts “Chop Lie” Cancer Control Elements In CCOP; RFA Delays Until After May NCAB Meeting

March 12, 1982

Prostate Ultrasound Markers Concepts Approved by BSC

October 3, 1986

Major Decisions On How NCI Will Spend Extra Money Won’t Be Made for Three-Four Months

November 4, 1983